Wed, September 23, 2009
Tue, September 22, 2009
Mon, September 21, 2009
Fri, September 18, 2009
Thu, September 17, 2009
Wed, September 16, 2009
Tue, September 15, 2009
Mon, September 14, 2009
Fri, September 11, 2009
Thu, September 10, 2009
Wed, September 9, 2009
Tue, September 8, 2009
Mon, September 7, 2009
Fri, September 4, 2009
Thu, September 3, 2009
Wed, September 2, 2009
Tue, September 1, 2009
Mon, August 31, 2009
Sun, August 30, 2009
Fri, August 28, 2009
Thu, August 27, 2009
Wed, August 26, 2009
Tue, August 25, 2009
Mon, August 24, 2009
Sun, August 23, 2009
Fri, August 21, 2009
Thu, August 20, 2009
Wed, August 19, 2009
Tue, August 18, 2009
Mon, August 17, 2009
Sun, August 16, 2009
Fri, August 14, 2009
Thu, August 13, 2009
Wed, August 12, 2009
Tue, August 11, 2009
Mon, August 10, 2009
Sun, August 9, 2009
Fri, August 7, 2009
Thu, August 6, 2009
Wed, August 5, 2009
Tue, August 4, 2009

Ranaz closes a private placement


  Copy link into your clipboard //house-home.news-articles.net/content/2009/09/01/ranaz-closes-a-private-placement.html
  Print publication without navigation Published in House and Home on by Market Wire
          🞛 This publication is a summary or evaluation of another publication

 MONTREAL, Sept. 1 /CNW Telbec/ - Ranaz Corporation ("Ranaz") (TSXV: RNZ), a company specializing in manufacturing and marketing of protein and dietary supplements, announces the closing of the (unbrokered) private placement announced on August 28, 2009, of 10,384,614 units at a price of $0.065 per unit for proceeds of $675 000. Each unit consists of one common share of Ranaz and one share purchase warrant at an exercise price of $0.10, expiring five years from its date of issuance. A maximum of 10,384,614 additional common shares of Ranaz may be issued under this private placement (assuming the exercise of all warrants). Securities issued under this private placement are subject to four-month hold period, ending on January 1, 2010. An insider of Ranaz, Fiducie Vanquish, subscribed approximately 70% of the private placement. This private placement was exempt from the valuation and minority shareholder approval under sections 5.5(a) and 5.7(a) of Regulation 61-101 respecting Protection of Minority Security Holders in Special Transactions, insofar the total consideration paid under the private placement represents less than 25% of the market capitalization of Ranaz. The objective of this private placement was to improve the liquidity condition of Ranaz. It was approved unanimously by the directors of Ranaz (including independent directors). About Ranaz Corporation Ranaz is a corporation specializing in the manufacture and sale of protein and dietary supplements. Its mission is to create, develop and sell nutritional, protein and dietary supplements under its own corporate brands, such as "Protidiet" and "Protilife", as well as under private brands. Forward-Looking Statements Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond Ranaz's control. Such risks include but are not limited to: the impact of general economic conditions, changes in the regulatory environment in the jurisdictions in which Ranaz does business, stock markets volatility, fluctuations in costs, and changes to the competitive environment due to consolidation, as well as other risks disclosed in public filings of Ranaz. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. The reader should not place undue reliance, if any, on the forward-looking statements included in this news release. These statements speak only as of the date made and Ranaz is under no obligation and disavows any intention to update or revise such statements as a result of any event, circumstances or otherwise. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. %SEDAR: 00024418EF 
For further information: Jean Bourassa-Marineau, President and Chief Executive Officer, (514) 666-8010 

Publication Contributing Sources

Similar House and Home Publications